EyeCRO CEO Rafal Farjo Named ARVO Foundation Chair

ByConnor Hodde

We are excited to announce that our CEO, Rafal Farjo, Ph.D., has been named the ARVO Foundation for Eye Research Chair. This prestigious appointment highlights Dr. Farjo’s extensive experience and dedication to advancing ocular research over the past 25 years. As the CEO of EyeCRO, Dr. Farjo has been instrumental in helping clients develop new ophthalmic therapeutics.

In his introductory letter, Dr. Farjo expressed his enthusiasm and commitment in his new role as Chair: “As I step into the role of Chair of the ARVO Foundation for Eye Research, I am filled with immense pride and a deep sense of responsibility. My esteemed predecessors have laid a strong groundwork for our organization with their vision and invaluable contributions. I am honored to build upon their legacy as we move forward together.”

ARVO is the leading global eye and vision research organization dedicated to understanding the visual system and preventing, treating, and curing its disorders. The ARVO Foundation supports innovative research, fosters collaboration, and nurtures the next generation of vision scientists. Join us in supporting the next generation of vision therapies by donating to the ARVO Foundation: Donate to the ARVO Foundation

Similar Posts

New Trial Shows Drugs are Effective for Diabetic Macular Edema

ByConnor Hodde

 Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy.  Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.  Over the past few…

Retinitis Pigmentosa Treatment: Retina Implants To Restore Sight Undergo Human Trials

ByConnor Hodde

Promising treatments for those blinded by an often-hereditary, retina-damaging disease are expanding throughout Europe and making their way across the pond, offering a ray of hope for the hundreds of thousands of people in the U.S. left in the dark by retinitis pigmentosa. The disease—which affects about one in 4,000 people in the U.S. and…

Calvert Labs and eyecro Announce Strategic Partnership in Ocular Research

ByConnor Hodde

Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities.  “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…

Rosemary Compound Shown To Help Fight Macular Degeneration In Mouse Model

ByConnor Hodde

A new study led by the Sanford-Burnham Medical Research Institute reports that carnosic acid, found in the herb rosemary, actually promotes eye health. Led by Dr. Stuart A. Lipton, the team found that carnosic acid protects the retina from degeneration and toxicity in cell culture and in rodent models of light-induced retinal damage. This suggests…

Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics

ByConnor Hodde

Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics.  “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic.  We intend on dosing our first patients for A1AT deficiency by the end of this year…

Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results

ByConnor Hodde

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read the entire…